Health Care • Medical Specialities
$24.72 ▲ +1.86
(+8.14%)
MKT CAP: $260.8M • VOL: 70.3K
52W L $5 52W H $32
ROARABLE / RQD
D • 44/100
PIOTROSKI
4 / 9
BDSX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $88.5M | $71.3M | $49.1M |
| YoY Revenue Growth % | +24.1% | +45.3% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$27.9M | -$34.5M | -$41.3M |
| Operating Margin % | -31.5% | -48.4% | -80.0% |
| Net Income (GAAP) | -$35.3M | -$42.9M | -$52.1M |
| EBITDA (Normalized) | -$27.7M | -$31.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$23.3M | -$48.6M | -$22.9M |
| Capital Expenditures (CapEx) | $259.0K | $3.2M | — |
| Free Cash Flow (FCF) | -$23.5M | -$51.9M | -$22.9M |
| FCF Margin % | -26.6% | -72.7% | -46.6% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $19.0M | $26.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$2.5M | $20.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BDSX.